Cardiff Oncology, Inc.
CRDF
$1.05
-$0.05-4.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -6.96% | -10.71% | -13.30% | -27.29% | -17.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.96% | -10.71% | -13.30% | -27.29% | -17.89% |
| Cost of Revenue | -31.42% | -31.42% | -51.49% | -29.52% | -18.67% |
| Gross Profit | 32.13% | 32.07% | 52.47% | 29.58% | 18.69% |
| SG&A Expenses | 24.89% | 22.22% | 13.96% | 16.76% | 12.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.06% | -8.99% | 0.44% | 15.09% | 21.16% |
| Operating Income | 22.21% | 8.97% | -0.64% | -15.72% | -21.74% |
| Income Before Tax | 21.50% | 8.38% | -0.92% | -17.31% | -24.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 21.50% | 8.38% | -0.92% | -17.31% | -24.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.50% | 8.38% | -0.92% | -17.31% | -24.87% |
| EBIT | 22.21% | 8.97% | -0.64% | -15.72% | -21.74% |
| EBITDA | 22.30% | 8.96% | -0.72% | -15.94% | -22.02% |
| EPS Basic | 32.98% | 28.82% | 28.24% | 15.98% | 3.48% |
| Normalized Basic EPS | 32.98% | 28.82% | 28.23% | 15.96% | 3.45% |
| EPS Diluted | 32.98% | 28.82% | 28.24% | 15.98% | 3.48% |
| Normalized Diluted EPS | 32.98% | 28.82% | 28.23% | 15.96% | 3.45% |
| Average Basic Shares Outstanding | 15.77% | 26.72% | 40.28% | 40.38% | 30.90% |
| Average Diluted Shares Outstanding | 15.77% | 26.72% | 40.28% | 40.38% | 30.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |